孙茂钢,邓雯,赵厚育

• 1:贵州医科大学
• 2:贵州医科大学附院耳鼻咽喉科

摘要(Abstract)：

<正>RNA干扰(RNA interference,RNAi)是在研究新小杆线虫双链RNA(double strand RNA,dsRNA)介导的基因出现表达抑制时首次被发现的,但由于这样的基因沉默是系统性的,当时有假设RNAi的效应是由一些稳定的中间媒介所调控的[1],后来才有更进一步的研究发现了这些中间媒介,例如

关键词(KeyWords)： 乙烯亚胺-四氧化三铁;磁性纳米粒;基因转染;鼻咽癌;缺氧诱导因子-1α;信使RNA

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金地区科学基金项目(NO.81260353)

作者(Author): 孙茂钢,邓雯,赵厚育

DOI: 10.19367/j.cnki.1000-2707.2016.04.002

参考文献(References)：

• [1]Dogini DB,Pascoal VD,Avansini SH,et al.The new world of RNAs[J].Genet Mol Biol,2014(Suppl1):285-293.
• [2]Sen GL,Blau,HM.A brief history of RNAi:the silence of the genes[J].FASEB,2006(9):1293-1299.
• [3]Resnier P,Montier T,Mathieu V,et al.A review of the current status of siRNA nanomedicines in the treatment of cancer[J].Biomaterials,2013(27):6429-6443.
• [4]Castanotto D,Rossi JJ.The promises and pitfalls of RNA-interference-based therapeutics[J].Nature,2009(7228):426-433.
• [5]Patil VS,Zhou R,Rana TM.Gene regulation by non-coding RNAs[J].Crit Rev Biochem Mol Biol,2014(1):16-32.
• [6]Pai SI.Prospects of RNA interference therapy for cancer[J].Gene Ther,2005(6):464-477.
• [7]Huang C.Role of nanoparticle geometry in endocytosis:laying down to stand up[J].Nano Lett,2013(9):4546-4550.
• [8]Uchino K,Ochiya T,Takeshita F.RNAi therapeutics and applications of MicroRNAs in cancer treatment[J].Jpn J Clin Oncol,2013(6):596-607.
• [9]Braakhuis HM,Park MV,Gosens I,et al.Physicochemical characteristics of nanomaterials that affect pulmonary inflammation[J].Part Fibre Toxicol,2014(18):1-25.
• [10]Tomalia D.In quest of a systematic framework for unifying and defining nanoscience[J].J Nanopart Res,2009(6):1251-1310.
• [11]Greish K.Enhanced permeability and retention of macromolecular drugs in solid tumors:a royal gate for targeted anticancer nanomedicines[J].J Drug Target,2007(7-8):457-464.
• [12]Felice B.Drug delivery vehicles on a nano-engineering perspective[J].Mater Sci Eng,2014(2):178-195.
• [13]Longmire M,Choyke PL,Kobayashi H.Clearance properties of nano-sized particles and molecules as imaging agents:considerations and caveats[J].Nanomedicine,2008(5):703-717.
• [14]Lian N.Application of dithizone-modified Ti O2 nanoparticles in the preconcentration of trace chromium and lead from sample solution and determination by inductively coupled plasma atomic emission spectrometry[J].Microchim Acta,2005(1-2):81-88.
• [15]Katas H,Alpar HO.Development and characterisation of chitosan nanoparticles for siRNA delivery[J].J Control Release,2006(2):216-225.
• [16]Whitehead KA,Langer R,Anderson DG.Knocking down barriers:advances in siRNA delivery[J].Nat Rev Drug Discov,2009(2):129-138.
• [17]Nam HY,Kwon SM,Chung H,et al.Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles[J].Control Release,2009(3):259-267.
• [18]Oh N,Park JH.Endocytosis and exocytosis of nanoparticles in mammalian cells[J].Int J Nanomed,2014(Suppl.1):51-63.
• [19]Guzman-Villanueva D,EI-Sherbiny IM,Herrera-Ruiz D,et al.Formulation approaches to short interfering RNA and MicroRNA:challenges and implications[J].J Pharm Sci,2012(11):4046-4066.
• [20]Zuckerman JE.Correlating animal and human phase Ia/Ib clinical data with CALAA-01,a targeted,polymerbased nanoparticle containing siRNA[J].Proc Natl Acad Sci USA,2014(31):11449-11454.
• [21]Chen Y,Zhu X,Zhang X,et al.Nanoparticles modified with tumor-targeting sc Fv deliver siRNA and miRNA for cancer therapy[J].Mol Ther,2010(9):1650-1656.
• [22]Bhujbal SV,de Vos P,Niclou SP.Drug and cell encapsulation:alternative delivery options for the treatment of malignant brain tumors[J].Adv Drug Deliv Rev,2014(2):142-153.
• [23]Gillespie,David L.RNA interference targeting hypoxiainducible factor 1 via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model[J].J Neurosurg,2015(2):331-341.
• [24]Simasi J.The role of BIM-EL and BCL2 on the efficacy of erlotinib and gefitinib in lung cancer[J].Respir Physiol Neurobiol,2015(10):64-68.
• [25]Bachelier R,Confavereux CB,Peyruchaud O,et al.Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis[J].Int J Cancer,2014(6):1319-1329.
• [26]Iyer AK,Khaled G,Fang J,et al.Exploiting the enhanced permeability and retention effect for tumor targeting[J].Drug Discov Today,2006(17-18):812-818.

文章评论(Comment)：